Molecular analysis of the massive GSH transport mechanism mediated by the human Multidrug Resistant Protein 1/ABCC1.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 05 2020
Historique:
received: 08 11 2019
accepted: 09 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 2 12 2020
Statut: epublish

Résumé

The transporter Multidrug Resistance Protein 1 (MRP1, ABCC1) is implicated in multidrug resistant (MDR) phenotype of cancer cells. Glutathione (GSH) plays a key role in MRP1 transport activities. In addition, a ligand-stimulated GSH transport which triggers the death of cells overexpressing MRP1, by collateral sensitivity (CS), has been described. This CS could be a way to overcome the poor prognosis for patients suffering from a chemoresistant cancer. The molecular mechanism of such massive GSH transport and its connection to the other transport activities of MRP1 are unknown. In this context, we generated MRP1/MRP2 chimeras covering different regions, MRP2 being a close homolog that does not trigger CS. The one encompassing helices 16 and 17 led to the loss of CS and MDR phenotype without altering basal GSH transport. Within this region, the sole restoration of the original G1228 (D1236 in MRP2) close to the extracellular loop between the two helices fully rescued the CS (massive GSH efflux and cell death) but not the MDR phenotype. The flexibility of that loop and the binding of a CS agent like verapamil could favor a particular conformation for the massive transport of GSH, not related to other transport activities of MRP1.

Identifiants

pubmed: 32377003
doi: 10.1038/s41598-020-64400-x
pii: 10.1038/s41598-020-64400-x
pmc: PMC7203140
doi:

Substances chimiques

Multidrug Resistance-Associated Proteins 0
Glutathione GAN16C9B8O
multidrug resistance-associated protein 1 Y49M64GZ4Q

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7616

Références

Ballatori, N., Krance, S. M., Marchan, R. & Hammond, C. L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol. Asp. Med. 30, 13–28, https://doi.org/10.1016/j.mam.2008.08.004 (2009).
doi: 10.1016/j.mam.2008.08.004
Cole, S. P. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu. Rev. pharmacology Toxicol. 54, 95–117, https://doi.org/10.1146/annurev-pharmtox-011613-135959 (2014).
doi: 10.1146/annurev-pharmtox-011613-135959
Haber, M. et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 24, 1546–1553, https://doi.org/10.1200/JCO.2005.01.6196 (2006).
doi: 10.1200/JCO.2005.01.6196 pubmed: 16575006
Leier, I. et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269, 27807–27810 (1994).
pubmed: 7961706
Loe, D. W., Deeley, R. G. & Cole, S. P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58, 5130–5136 (1998).
pubmed: 9823323
Manciu, L. et al. Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. J. Biol. Chem. 278, 3347–3356 (2003).
pubmed: 12424247
Mueller, C. F. et al. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circulation Res. 97, 637–644, https://doi.org/10.1161/01.RES.0000183734.21112.b7 (2005).
doi: 10.1161/01.RES.0000183734.21112.b7 pubmed: 16123331
Loe, D. W., Deeley, R. G. & Cole, S. P. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 293, 530–538 (2000).
pubmed: 10773025
Rothnie, A., Callaghan, R., Deeley, R. G. & Cole, S. P. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 281, 13906–13914, https://doi.org/10.1074/jbc.M600869200 (2006).
doi: 10.1074/jbc.M600869200 pubmed: 16565074
Rothnie, A., Conseil, G., Lau, A. Y., Deeley, R. G. & Cole, S. P. Mechanistic differences between GSH transport by multidrug resistance protein 1 (MRP1/ABCC1) and GSH modulation of MRP1-mediated transport. Mol. Pharmacol. 74, 1630–1640, https://doi.org/10.1124/mol.108.049080 (2008).
doi: 10.1124/mol.108.049080 pubmed: 18768387
Perrotton, T., Trompier, D., Chang, X. B., Di Pietro, A. & Baubichon-Cortay, H. R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J. Biol. Chem. 282, 31542–31548, https://doi.org/10.1074/jbc.M703964200 (2007).
doi: 10.1074/jbc.M703964200 pubmed: 17646169
Trompier, D. et al. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res. 64, 4950–4956, https://doi.org/10.1158/0008-5472.CAN-04-0143 (2004).
doi: 10.1158/0008-5472.CAN-04-0143 pubmed: 15256468
Szybalski, W. & Bryson, V. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J. Bacteriol. 64, 489–499 (1952).
pubmed: 12999676 pmcid: 169383
Szakacs, G. et al. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem. Rev. 114, 5753–5774, https://doi.org/10.1021/cr4006236 (2014).
doi: 10.1021/cr4006236 pubmed: 24758331 pmcid: 4059772
Lorendeau, D. et al. MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion. Curr. Med. Chem. 24, 1186–1213 (2017).
pubmed: 27855620
Marchan, R., Hammond, C. L. & Ballatori, N. Multidrug resistance-associated protein 1 as a major mediator of basal and apoptotic glutathione release. Biochimica et. biophysica acta 1778, 2413–2420, https://doi.org/10.1016/j.bbamem.2008.06.011 (2008).
doi: 10.1016/j.bbamem.2008.06.011 pubmed: 18621020 pmcid: 2574834
Cao, J. Y. et al. A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity. Cell Rep. 26, 1544–1556 e1548, https://doi.org/10.1016/j.celrep.2019.01.043 (2019).
doi: 10.1016/j.celrep.2019.01.043 pubmed: 30726737 pmcid: 6424331
Dury, L. et al. Flavonoid dimers are highly potent killers of multidrug resistant cancer cells overexpressing MRP1. Biochem. Pharmacol. 124, 10–18 (2017).
pubmed: 27984000
Bandler, P. E., Westlake, C. J., Grant, C. E., Cole, S. P. C. & Deeley, R. G. Identification of Regions Required for Apical Membrane Localization of Human Multidrug Resistance Protein 2. Mol. Pharmacology 74, 9–19, https://doi.org/10.1124/mol.108.045674 (2008).
doi: 10.1124/mol.108.045674
Grant, C. E., Gao, M., DeGorter, M. K., Cole, S. P. & Deeley, R. G. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug. Metab. Dispos. 36, 2571–2581, https://doi.org/10.1124/dmd.108.022491 (2008).
doi: 10.1124/dmd.108.022491 pubmed: 18775981
Paulusma, C. C. et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338(Pt 2), 393–401 (1999).
pubmed: 10024515 pmcid: 1220065
Cole, S. P. & Deeley, R. G. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27, 438–446, https://doi.org/10.1016/j.tips.2006.06.008 (2006).
doi: 10.1016/j.tips.2006.06.008 pubmed: 16820223
Ito, K., Horie, T., Suzuki, H. & Sugiyama, Y. Polarized expression of drug transporters and its physiological significance. Tanpakushitsu Kakusan Koso 48, 122–132 (2003).
pubmed: 12638176
Lou, H., Ookhtens, M., Stolz, A. & Kaplowitz, N. Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells. Am. J. Physiol. Gastrointest. Liver Physiol 285, G1335–1344, https://doi.org/10.1152/ajpgi.00271.2003 (2003).
doi: 10.1152/ajpgi.00271.2003 pubmed: 12893631
Wielandt, A. M. et al. Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5-trichlorophenoxyacetic acid in the mouse liver. Biochem. J. 341(Pt 1), 105–111 (1999).
pubmed: 10377250 pmcid: 1220335
Yang, B. & Hill, C. E. Nifedipine modulation of biliary GSH and GSSG/conjugate efflux in normal and regenerating rat liver. Am. J. Physiol. Gastrointest. Liver Physiol 281, G85–94 (2001).
pubmed: 11408258
Cui, Y. et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55, 929–937 (1999).
pubmed: 10220572
Bakos, E. et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57, 760–768 (2000).
pubmed: 10727523
Koike, K. et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57, 5475–5479 (1997).
pubmed: 9407953
Kawabe, T. et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 456, 327–331 (1999).
pubmed: 10456333
Karwatsky, J., Daoud, R., Cai, J., Gros, P. & Georges, E. Binding of a photoaffinity analogue of glutathione to MRP1 (ABCC1) within two cytoplasmic regions (L0 and L1) as well as transmembrane domains 10-11 and 16-17. Biochemistry 42, 3286–3294 (2003).
pubmed: 12641460
Karwatsky, J. M. & Georges, E. Drug binding domains of MRP1 (ABCC1) as revealed by photoaffinity labeling. Curr. Med. Chem. Anticancer. Agents 4, 19–30 (2004).
pubmed: 14754409
Wu, P. et al. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: toward identification of leukotriene C4 binding sites. Mol. Pharmacol. 68, 1455–1465, https://doi.org/10.1124/mol.105.016576 (2005).
doi: 10.1124/mol.105.016576 pubmed: 16105987
Conseil, G., Rothnie, A. J., Deeley, R. G. & Cole, S. P. Multiple roles of charged amino acids in cytoplasmic loop 7 for expression and function of the multidrug and organic anion transporter MRP1 (ABCC1). Mol. Pharmacol. 75, 397–406, https://doi.org/10.1124/mol.108.052860 (2009).
doi: 10.1124/mol.108.052860 pubmed: 19015228
Iram, S. H. & Cole, S. P. Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 287, 7543–7555, https://doi.org/10.1074/jbc.M111.310409 (2012).
doi: 10.1074/jbc.M111.310409 pubmed: 22232552 pmcid: 3293527
Baiceanu, E. et al. 2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2. Eur. J. Med. Chem. 122, 408–418, https://doi.org/10.1016/j.ejmech.2016.06.039 (2016).
doi: 10.1016/j.ejmech.2016.06.039 pubmed: 27393949
Iram, S. H. & Cole, S. P. Differential functional rescue of Lys(513) and Lys(516) processing mutants of MRP1 (ABCC1) by chemical chaperones reveals different domain-domain interactions of the transporter. Biochimica et. biophysica acta 1838, 756–765, https://doi.org/10.1016/j.bbamem.2013.11.002 (2014).
doi: 10.1016/j.bbamem.2013.11.002 pubmed: 24231430
Conseil, G., Deeley, R. G. & Cole, S. P. Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 281, 43–50, https://doi.org/10.1074/jbc.M510143200 (2006).
doi: 10.1074/jbc.M510143200 pubmed: 16230346
Srinivasan, V., Pierik, A. J. & Lill, R. Crystal structures of nucleotide-free and glutathione-bound mitochondrial ABC transporter Atm1. Science 343, 1137–1140, https://doi.org/10.1126/science.1246729 (2014).
doi: 10.1126/science.1246729 pubmed: 24604199
Johnson, Z. L. & Chen, J. Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1. Cell 168, 1075–1085 e1079, https://doi.org/10.1016/j.cell.2017.01.041 (2017).
doi: 10.1016/j.cell.2017.01.041 pubmed: 28238471
Laberge, R.-M., Karwatsky, J., Lincoln, M. C., Leimanis, M. L. & Georges, E. Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochemical Pharmacology 73, 1727–1737, https://doi.org/10.1016/j.bcp.2007.02.005 (2007).
doi: 10.1016/j.bcp.2007.02.005 pubmed: 17359940
Rappa, G. et al. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Eur. J. Cancer 39, 120–128 (2003).
pubmed: 12504668
Lee, J. Y., Yang, J. G., Zhitnitsky, D., Lewinson, O. & Rees, D. C. Structural basis for heavy metal detoxification by an Atm1-type ABC exporter. Science 343, 1133–1136, https://doi.org/10.1126/science.1246489 (2014).
doi: 10.1126/science.1246489 pubmed: 24604198 pmcid: 4151877
Johnson, Z. L. & Chen, J. ATP Binding Enables Substrate Release from Multidrug Resistance Protein 1. Cell 172, 81–89 e10, https://doi.org/10.1016/j.cell.2017.12.005 (2018).
doi: 10.1016/j.cell.2017.12.005 pubmed: 29290467
Yang, J., Song, P. & Zhou, G. A study on the correlations of MRP-1 expression with the pathogenesis and prognosis of colorectal cancer. J. BUON 24, 84–90 (2019).
pubmed: 30941955
Iram, S. H. & Cole, S. P. Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J. Biol. Chem. 286, 7202–7213, https://doi.org/10.1074/jbc.M110.166959 (2011).
doi: 10.1074/jbc.M110.166959 pubmed: 21177244
Westlake, C. J. et al. Identification of the structural and functional boundaries of the multidrug resistance protein 1 cytoplasmic loop 3. Biochemistry 42, 14099–14113 (2003).
pubmed: 14640677
Sauna, Z. E. & Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 12, 683–691 (2011).
pubmed: 21878961
Ito, K., Olsen, S. L., Qiu, W., Deeley, R. G. & Cole, S. P. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 276, 15616–15624 (2001).
pubmed: 11278867
Gyimesi, G. et al. ABCMdb: a database for the comparative analysis of protein mutations in ABC transporters, and a potential framework for a general application. Hum. Mutat. 33, 1547–1556, https://doi.org/10.1002/humu.22138 (2012).
doi: 10.1002/humu.22138 pubmed: 22693078
Qian, Y. M. et al. Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione. J. Biol. Chem. 277, 35225–35231 (2002).
pubmed: 12138119
Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427 (1993).
pubmed: 8102521
Mao, Q. et al. GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J. Biol. Chem. 277, 28690–28699 (2002).
pubmed: 12034727
Wong, I. L. et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J. Med. Chem. 52, 5311–5322, https://doi.org/10.1021/jm900194w (2009).
doi: 10.1021/jm900194w pubmed: 19725578
Zhang, Z. & Chen, J. Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator. Cell 167, 1586–1597 (2016).
pubmed: 27912062
Zhang, Z., Liu, F. & Chen, J. Conformational Changes of CFTR upon Phosphorylation and ATP Binding. Cell 170, 483–491 e488, https://doi.org/10.1016/j.cell.2017.06.041 (2017).
doi: 10.1016/j.cell.2017.06.041 pubmed: 28735752
Mao, Q., Leslie, E. M., Deeley, R. G. & Cole, S. P. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochimica et. biophysica acta 1461, 69–82 (1999).
pubmed: 10556489
Weigl, K. E. et al. An Outward-Facing Aromatic Amino Acid Is Crucial for Signaling between the Membrane-Spanning and Nucleotide-Binding Domains of Multidrug Resistance Protein 1 (MRP1; ABCC1). Mol. Pharmacol. 94, 1069–1078, https://doi.org/10.1124/mol.118.112615 (2018).
doi: 10.1124/mol.118.112615 pubmed: 29976562
Baiceanu, E. et al. 2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2. Eur J Med Chem, 408–418 (2016).
Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113, 548–555 (1985).
pubmed: 4088074
Lorendeau, D. et al. Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux. Biochemical pharmacology 90, 235–245, https://doi.org/10.1016/j.bcp.2014.05.017 (2014).
doi: 10.1016/j.bcp.2014.05.017 pubmed: 24875445
Chan, K. F. et al. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells. J. medicinal Chem. 49, 6742–6759, https://doi.org/10.1021/jm060593+ (2006).
doi: 10.1021/jm060593+
Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. Curr. Protoc. Bioinforma. 54, 5.6.1–5.6.37 (2016).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr 66, 486–501 (2010).
pubmed: 20383002 pmcid: 2852313
Nicholls, R. A., Long, F. & Murshudov, G. N. Low resolution refinement tools in REFMAC5. Acta Crystallogr. D. Biol. Crystallogr 68, 404–417 (2012).
pubmed: 22505260 pmcid: 3322599

Auteurs

Rachad Nasr (R)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.

Doriane Lorendeau (D)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.

Ruttiros Khonkarn (R)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, 50200, Thailand.

Lauriane Dury (L)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.

Basile Pérès (B)

Department of Molecular Pharmacochemistry (DPM), UMR 5063, Grenoble Alpes University, 38041, Grenoble, France.

Ahcène Boumendjel (A)

Department of Molecular Pharmacochemistry (DPM), UMR 5063, Grenoble Alpes University, 38041, Grenoble, France.

Jean-Claude Cortay (JC)

INSERM U1052, CNRS-University of Lyon UMR-5286, Cancer Research Center of Lyon (CRCL), 69008, Lyon, France.

Pierre Falson (P)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.

Vincent Chaptal (V)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France.

Hélène Baubichon-Cortay (H)

Drug Resistance and Membrane Proteins group, IBCP, UMR 5086, CNRS-University of Lyon, 69367, Lyon, France. h.cortay@ibcp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH